These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

LAS VEGAS, NV / / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ('Avant' or the 'Company'), and its partner, Ainnova Tech, Inc., (Ai ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Beyond Stargate's big players, a growing number of innovators have been revolutionizing healthcare by making recent ...